On the inhibition of 5-lipoxygenase product formation by tryptanthrin: Mechanistic studies and efficacy in vivo

British Journal of Pharmacology

Volumn 165, Issue 3, 2012, Pages 765-776

  Pergola, C ^a   Jazzar, B ^b   Rossi, Antonietta ^c   Northoff, H ^d   Hamburger, M ^e   Sautebin, L ^c   Werz, O ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

5 lipoxygenase; inflammation; leukotriene; tryptanthrin

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CALCIUM ION; CARRAGEENAN; FORMYLPEPTIDE; I KAPPA B ALPHA; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN E2; SYNAPTOTAGMIN I; TRYPTANTHRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FREE SYSTEM; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID SYNTHESIS; FATTY ACID SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE ACTIVATION; NONHUMAN; OXIDATION REDUCTION STATE; PLEURISY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

EID: 84855645423     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01605.x     Document Type: Article

References (50)

1. Bandekar PP, Roopnarine KA, Parekh VJ, Mitchell TR, Novak MJ, Sinden RR, (2010). Antimicrobial activity of tryptanthrins in Escherichia coli. J Med Chem 53: 3558-3565.
2. Benjamim CF, Canetti C, Cunha FQ, Kunkel SL, Peters-Golden M, (2005). Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis. J Immunol 174: 1616-1620.
3. Bergman J, Lindstrom JO, Tilstam U, (1985). The structure and properties of some indolic constituents in Couroupita-Guianensis Aubl. Tetrahedron 41: 2879-2881.
4. Blois MS, (1958). Antioxidant determinations by the use of a stable free radical. Nature 181: 1199-1200.
5. Brungs M, Radmark O, Samuelsson B, Steinhilber D, (1995). Sequential induction of 5-lipoxygenase gene expression and activity in Mono Mac 6 cells by transforming growth factor beta and 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 92: 107-111.
6. Bryn T, Mahic M, Enserink JM, Schwede F, Aandahl EM, Tasken K, (2006). The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J Immunol 176: 7361-7370. (Pubitemid 43849037)
7. Chan HL, Yip HY, Mak NK, Leung KN, (2009). Modulatory effects and action mechanisms of tryptanthrin on murine myeloid leukemia cells. Cell Mol Immunol 6: 335-342.
8. Danz H, Stoyanova S, Wippich P, Brattstrom A, Hamburger M, (2001). Identification and isolation of the cyclooxygenase-2 inhibitory principle in Isatis tinctoria. Planta Med 67: 411-416. (Pubitemid 32652575)
9. Danz H, Baumann D, Hamburger M, (2002a). Quantitative determination of the dual COX-2/5-LOX inhibitor tryptanthrin in Isatis tinctoria by ESI-LC-MS. Planta Med 68: 152-157. (Pubitemid 34169409)
10. Danz H, Stoyanova S, Thomet OA, Simon HU, Dannhardt G, Ulbrich H, et al,. (2002b). Inhibitory activity of tryptanthrin on prostaglandin and leukotriene synthesis. Planta Med 68: 875-880. (Pubitemid 35239275)
11. Drazen JM, Israel E, O'Byrne PM, (1999). Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340: 197-206. (Pubitemid 29063217)
12. Feisst C, Pergola C, Rakonjac M, Rossi A, Koeberle A, Dodt G, et al,. (2009). Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo. Cell Mol Life Sci 66: 2759-2771.
13. Fischer L, Szellas D, Radmark O, Steinhilber D, Werz O, (2003). Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J 17: 949-951.
14. Fischer L, Steinhilber D, Werz O, (2004). Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol 142: 861-868. (Pubitemid 39004096)
15. 2+mobilisation in polymorphonuclear leukocytes involving Src family kinases. Biochim Biophys Acta 1736: 109-119. (Pubitemid 41262568)
16. Fischer L, Hornig M, Pergola C, Meindl N, Franke L, Tanrikulu Y, et al,. (2007). The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br J Pharmacol 152: 471-480. (Pubitemid 47585043)
17. Fischer A, Metzner J, Steinbrink S, Ulrich S, Angioni C, Geisslinger G, et al,. (2010). 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. Br J Pharmacol 161: 936-949.
18. Greiner C, Hornig C, Rossi A, Pergola C, Zettl H, Schubert-Zsilavecz M, et al,. (2011). 2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52)-a novel type 5-lipoxygenase inhibitor with favorable molecular pharmacology and efficacy in vivo. Br J Pharmacol 164: 781-793.
19. 2+indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450. (Pubitemid 15114340)
20. Honda G, Tabata M, (1979). Isolation of antifungal principle tryptanthrin, from Strobilanthes cusia O. Kuntze. Planta Med 36: 85-90.
21. 4synthase. J Med Chem 38: 4538-4547.
22. 2synthesis by murine macrophages. Eur J Pharmacol 407: 197-204.
23. Jao CW, Lin WC, Wu YT, Wu PL, (2008). Isolation, structure elucidation, and synthesis of cytotoxic tryptanthrin analogues from Phaius mishmensis. J Nat Prod 71: 1275-1279.
24. Kargman S, Prasit P, Evans JF, (1991). Translocation of HL-60 cell 5-lipoxygenase. Inhibition of A23187- or N-formyl-methionyl-leucyl- phenylalanine-induced translocation by indole and quinoline leukotriene synthesis inhibitors. J Biol Chem 266: 23745-23752. (Pubitemid 21908860)
25. Lee SK, Kim GH, Kim DH, Jahng Y, Jeong TC, (2007). Identification of a tryptanthrin metabolite in rat liver microsomes by liquid chromatography/ electrospray ionization-tandem mass spectrometry. Biol Pharm Bull 30: 1991-1995. (Pubitemid 47607793)
26. McMillan RM, Walker ER, (1992). Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci 13: 323-330.
27. Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, et al,. (1993). 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett 318: 277-281. (Pubitemid 23071752)
28. Micallef MJ, Iwaki K, Ishihara T, Ushio S, Aga M, Kunikata T, et al,. (2002). The natural plant product tryptanthrin ameliorates dextran sodium sulfate-induced colitis in mice. Int Immunopharmacol 2: 565-578. (Pubitemid 34169751)
29. Molina P, Tarraga A, Gonzalez-Tejero A, Rioja I, Ubeda A, Terencio MC, et al,. (2001). Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives. J Nat Prod 64: 1297-1300. (Pubitemid 33029210)
30. Murakami T, Kishi A, Sakurama T, Matsuda H, Yoshikawa M, (2001). Chemical constituents of two oriental orchids, Calanthe discolor and C. liukiuensis: precursor indole glycoside of tryptanthrin and indirubin. Heterocycles 54: 957-966. (Pubitemid 32249320)
31. Pergola C, Werz O, (2010). 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin Ther Pat 20: 355-375.
32. Pergola C, Dodt G, Rossi A, Neunhoeffer E, Lawrenz B, Northoff H, et al,. (2008). ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci USA 105: 19881-19886.
33. Peters-Golden M, Henderson WR Jr, (2007). Leukotrienes. N Engl J Med 357: 1841-1854.
34. Radmark O, Werz O, Steinhilber D, Samuelsson B, (2007). 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 32: 332-341. (Pubitemid 47021417)
35. Recio MC, Cerda-Nicolas M, Potterat O, Hamburger M, Rios JL, (2006). Anti-inflammatory and antiallergic activity in vivo of lipophilic Isatis tinctoria extracts and tryptanthrin. Planta Med 72: 539-546. (Pubitemid 43844682)
36. Schindler F, Zahner H, (1971). [Metabolic products of microorganisms. 91. Tryptanthrin, a tryptophan derived antibiotic from Candida lipolytica]. Arch Mikrobiol 79: 187-203.
37. Siemoneit U, Pergola C, Jazzar B, Northoff H, Skarke C, Jauch J, et al,. (2009). On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance. Eur J Pharmacol 606: 246-254.
38. Surette ME, Palmantier R, Gosselin J, Borgeat P, (1993). Lipopolysaccharides prime whole human blood and isolated neutrophils for the increased synthesis of 5-lipoxygenase products by enhancing arachidonic acid availability: involvement of the CD14 antigen. J Exp Med 178: 1347-1355. (Pubitemid 23277366)
39. Takei Y, Kunikata T, Aga M, Inoue S, Ushio S, Iwaki K, et al,. (2003). Tryptanthrin inhibits interferon-gamma production by Peyer's patch lymphocytes derived from mice that had been orally administered staphylococcal enterotoxin. Biol Pharm Bull 26: 365-367. (Pubitemid 39663626)
40. Vancurova I, Miskolci V, Davidson D, (2001). NF-kappa B activation in tumor necrosis factor alpha-stimulated neutrophils is mediated by protein kinase Cdelta. Correlation to nuclear Ikappa Balpha. J Biol Chem 276: 19746-19752.
41. Werz O, (2002). 5-lipoxygenase: cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy 1: 23-44.
42. Werz O, (2007). Inhibition of 5-lipoxygenase product synthesis by natural compounds of plant origin. Planta Med 73: 1331-1357. (Pubitemid 350084452)
43. Werz O, Steinhilber D, (2005). Development of 5-lipoxygenase inhibitors-lessons from cellular enzyme regulation. Biochem Pharmacol 70: 327-333. (Pubitemid 40908906)
44. Werz O, Steinhilber D, (2006). Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 112: 701-718. (Pubitemid 44592614)
45. Werz O, Szellas D, Henseler M, Steinhilber D, (1998). Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol 54: 445-451. (Pubitemid 28368835)
46. Werz O, Klemm J, Samuelsson B, Radmark O, (2001). Phorbol ester up-regulates capacities for nuclear translocation and phosphorylation of 5-lipoxygenase in Mono Mac 6 cells and human polymorphonuclear leukocytes. Blood 97: 2487-2495. (Pubitemid 32291497)
47. Werz O, Burkert E, Fischer L, Szellas D, Dishart D, Samuelsson B, et al,. (2002a). Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes. FASEB J 16: 1441-1443.
48. Werz O, Burkert E, Samuelsson B, Radmark O, Steinhilber D, (2002b). Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 99: 1044-1052. (Pubitemid 34527142)
49. Yu ST, Chen TM, Tseng SY, Chen YH, (2007). Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun 358: 79-84.
50. Yu ST, Chen TM, Chern JW, Tseng SY, Chen YH, (2009). Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-mediated apoptosis. Anticancer Drugs 20: 382-388.